Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

The therapeutic effect of thalidomide in chronic discoid lupus erythematosus (CDLE) was studied in sixty patients who were followed up for 2 years. In fifty‐four patients (90%) a complete or marked regression of the disease was observed, but when the thalidomide was stopped, thirty out of forty‐one (71%) patients relapsed. Patients undergoing a second course of thalidomide treatment again responded well. Nine of the patients in whom the disease recurred after successful treatment with thalidomide and who had been unresponsive to intermittent treatment with antimalarials, showed a good response to a second or third course with thalidomide. Mild side‐effects were common and 25% of patients complained of slight to moderate polyneuritic symptoms. Since electroneurological examinations had not been performed before the thalidomide therapy, the frequency of neurological side‐effects cannot be accurately calculated but we recommend neurological examinations before and periodically during thalidomide treatment.

[1]  J. Sheskin,et al.  [Motor-conduction velocity of cubital nerves in patients with leprosy reactions. Summary of a 13-year observation series during thalidomide therapy]. , 1979, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[2]  J. Sheskin.  [Therapeutic experience on the effect of thalidomidomide on lepra reaction]. , 1975, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[3]  W. Amelung,et al.  [Clinical aspects and therapy of the so-called Contergan-polyneuropathy]. , 1966, Der Nervenarzt.

[4]  D. O'Sullivan,et al.  Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. , 1968, Journal of neurology, neurosurgery, and psychiatry.